Oncoimmunology: A Practical Guide for Cancer Immunotherapy

Description

In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. Front Matter ....Pages i-x Principles of Oncoimmunology (Laurence Zitvogel, Guido Kroemer)....Pages 1-2 Front Matter ....Pages 3-3 The Human Tumor Microenvironment (Yann Vano, Nicolas A. Giraldo, Wolf Herman Fridman, Catherine Sautès-Fridman)....Pages 5-21 CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy (Weimin Wang, Michael Green, J. Rebecca Liu, Theodore S. Lawrence, Weiping Zou)....Pages 23-39 Mutant Epitopes in Cancer (Martin Rao, Liu Zhenjiang, Qingda Meng, Georges Sinclair, Ernest Dodoo, Markus Maeurer)....Pages 41-67 The Secrets of T Cell Polarization (Thaiz Rivera Vargas, Lionel Apetoh)....Pages 69-95 Regulatory T Cells: Their Role, Mechanism of Action, and Impact on Cancer (Anthony R. Cillo, Dario A. A. Vignali)....Pages 97-113 Purinergic Receptors: Novel Targets for Cancer Immunotherapy (Dipti Vijayan, Mark J. Smyth, Michele W. L. Teng)....Pages 115-141 Plasmacytoid DC/Regulatory T Cell Interactions at the Center of an Immunosuppressive Network in Breast and Ovarian Tumors (N. Bendriss-Vermare, N. Gourdin, N. Vey, J. Faget, V. Sisirak, I. Labidi-Galy et al.)....Pages 143-161 Cancer Immunosurveillance by Natural Killer Cells and Other Innate Lymphoid Cells (Camille Guillerey, Mark J. Smyth)....Pages 163-180 Biology of Myeloid-Derived Suppressor Cells (Kevin Alicea-Torres, Dmitry I. Gabrilovich)....Pages 181-197 Effect of Pharmaceutical Compounds on Myeloid-Derived Suppressor Cells (Mélanie Bruchard, Francois Ghiringhelli)....Pages 199-213 Immunogenic Stress and Death of Cancer Cells in Natural and Therapy-Induced Immunosurveillance (Oliver Kepp, Jonathan Pol, Laurence Zitvogel, Guido Kroemer)....Pages 215-229 Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies (Anna S. Berghoff, Jakob Nikolas Kather, Dirk Jäger)....Pages 231-246 Front Matter ....Pages 247-247 Peptide-Based Therapeutic Cancer Vaccines (Cornelis J. M. Melief)....Pages 249-261 Cancer Vaccines for HPV Malignancies (Maria Agarwal, Cornelia Trimble)....Pages 263-274 NK Cell-Based Therapies (Laura Chiossone, Eric Vivier)....Pages 275-288 IDO/TDO Inhibition in Cancer (George C. Prendergast, William J. Malachowski, Arpita Mondal, Peggy Scherle, Alexander J. Muller)....Pages 289-307 Front Matter ....Pages 309-309 Tumor-Targeted Antibodies (Aurélien Marabelle)....Pages 311-319 PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies (Annette Paschen, Dirk Schadendorf)....Pages 321-331 Immune Checkpoint Inhibition in Lung Cancer (Daniel Morgensztern, Roy S. Herbst)....Pages 333-344 PD-1 Blockade in Renal Cell Carcinoma (Lisa Derosa, Bernard Escudier)....Pages 345-355 BCG and Anti-PDL-1 Ab in Bladder Cancers (Pernelle Lavaud, Yohann Loriot)....Pages 357-369 PD-L1 and Other Immunological Diagnosis Tools (Nicolas A. Giraldo, Janis M. Taube)....Pages 371-385 Oncolytic Viruses: T-VEC and Others (Rutika Mehta, Igor Puzanov)....Pages 387-403 Front Matter ....Pages 405-405 Innate Immune Receptors in the Regulation of Tumor Immunity (Sho Hangai, Yoshitaka Kimura, Tadatsugu Taniguchi, Hideyuki Yanai)....Pages 407-427 Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer (Ignacio Melero, Elisabeth Pérez-Ruiz, Alfonso R. Sanchez-Paulete, Alvaro Teijeira, Angela Aznar, Miguel F. Sanmamed)....Pages 429-446 The Impact of the Intestinal Microbiota in Therapeutic Responses Against Cancer (Mélodie Bonvalet, Romain Daillère, Maria P. Roberti, Conrad Rauber, Laurence Zitvogel)....Pages 447-462 Local Immunotherapies of Cancer (Thomas U. Marron, Linda Hammerich, Joshua Brody)....Pages 463-481 Strategies to Reduce Intratumoral Regulatory T Cells (C. Maherzi, F. Onodi, E. Tartour, M. Terme, C. Tanchot)....Pages 483-506 Synergy Between Radiotherapy and Immunotherapy (Sandra Demaria, Sophia Bornstein, Silvia C. Formenti)....Pages 507-524 Predictors of Response to Immune Checkpoint Blockade (Miles C. Andrews, Jennifer A. Wargo)....Pages 525-544 Front Matter ....Pages 545-545 Immune Therapies in Phase 1 Trials (Sophie Postel-Vinay, Jean-Charles Soria)....Pages 547-563 Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors (Lucia Festino, Paolo A. Ascierto)....Pages 565-578 Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting (Alexander M. M. Eggermont, Caroline Robert)....Pages 579-591 Immunotherapy for Prostate Cancer: An Evolving Landscape (Wendy Mao, Charles G. Drake)....Pages 593-606 Challenges of Oncoimmunology for Ovarian and Breast Cancers (Mathilde Saint-Ghislain, Marie Bretagne, Marie-Paule Sablin, Emanuela Romano)....Pages 607-619 Challenges in Colorectal Cancer: From Vaccines to Macrophage Repolarization (Niels Halama)....Pages 621-639 Current Status of Immuno-Oncology in Hematologic Cancers (Bertrand Routy, David Ghez)....Pages 641-655 Immunotherapy of Gliomas (Michael Platten)....Pages 657-664 Assessing T Cell Receptor Affinity and Avidity Against Tumor Antigens (Mathilde Allard, Michael Hebeisen, Nathalie Rufer)....Pages 665-679 Immune Monitoring of Blood and Tumor Microenvironment (Petra Baumgaertner, Kalliopi Ioannidou, Daniel E. Speiser)....Pages 681-694 Toward Engineered Cells as Transformational and Broadly Available Medicines for the Treatment of Cancer (Cedrik M. Britten, Laura A. Johnson, Alfonso Quintás-Cardama, Neil C. Sheppard, Axel Hoos)....Pages 695-717 Front Matter ....Pages 719-719 Concluding Remarks (Pedro Romero, Wolf H. Fridman)....Pages 721-724